Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bazedoxifene Plus Conjugated Estrogens for Breast Cancer Risk Reduction
NCT04821141Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Dec 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bazedoxifene, conjugated estrogens in breast cancer, sponsored by University of Kansas Medical Center. Started Dec 2021; status: active, not recruiting.
02
Drugs
bazedoxifeneconjugated estrogens
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04821141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821141.